Statins (HMG-CoA reductase inhibitors) - a class of drug used to lower cholesterol levels

Statins (or HMG-CoA reductase inhibitors) are a class of drug used to lower cholesterol levels by inhibiting the enzyme HMG-CoA reductase, which plays a central role in the production of cholesterol...

The Top 100 Drugs

The pharmaceutical industry is massive, both in range of products and in financial values. These are the top 200 drugs (ranked in descending order according to total sales in 20010, $), and the co...

BMI No Issue for Vytorin in Diabetes (CME/CE)

BERLIN (MedPage Today) -- Whether a diabetic patient is obese or non-obese, treatment with the combination of ezetimibe/simvastatin (Vytorin) works consistently to reduce cholesterol levels, researche...

Panel Clears Merck's Vytorin Trial to Continue

A closely watched clinical trial for Merck's cholesterol-lowering blockbuster Vytorin was cleared to proceed by a safety board overseeing the research.

Merck Vytorin study to continue after panel review

(Reuters) - Pharmaceutical company Merck & Co Inc said on Tuesday an independent monitoring board had allowed it to continue with a large trial assessing the safety and effectiveness of its Vytorin ch...

Vytorin study to continue after review; Merck shares jump

(Reuters) - An independent monitoring board said a large trial of Merck & Co's Vytorin cholesterol drug can continue, suggesting no major safety issues have yet been seen with the pill.

UPDATE 2-Vytorin study to continue after review; Merck shares jump

March 12 (Reuters) - An independent monitoring board said a large trial of Merck & Co's Vytorin cholesterol drug can continue, suggesting no major safety issues have yet been seen with the pill.

UPDATE 1-Merck Vytorin study to continue after panel review

March 12 (Reuters) - Pharmaceutical company Merck & Co Inc said on Tuesday an independent monitoring board had allowed it to continue with a large trial assessing the safety and effectiveness of its...

Merck will continue large study of Vytorin after panel review

March 12 (Reuters) - Pharmaceutical company Merck & Co Inc said on Tuesday that an independent monitoring board had allowed it to continue with a huge trial assessing the safety and effectiveness of...

Merck & Co to pay $688 million to settle Vytorin lawsuits

Merck & Co to pay $688 million to settle Vytorin lawsuits

Treatment of familial hypercholesterolaemia in children and adolescents in the last three decades.

Background: This study evaluated the effectiveness of long-term intensive lipid-lowering therapy in children and adolescents with familial hypercholesterolaemia. Methods: The charts of 89 children and...

Lipid modification in the elderly using the combination of a statin and a cholesterol absorption inhibitor.

While the optimal lipid-lowering treatment to reduce cardiovascular disease (CVD) risk in elderly patients has not been definitively established, evidence so far indicates that reducing low-density li...